Down-regulation of CMTM8 induces epithelial-to-mesenchymal transition-like changes via c-MET/extracellular signal-regulated kinase (ERK) signaling

Journal of Biological Chemistry

Volumn 287, Issue 15, 2012, Pages 11850-11858

  Zhang, Wenjuan ^a,c   Mendoza, Michelle C ^b   Pei, Xiaolei ^a   Ilter, Didem ^b   Mahoney, Sarah J ^b   Zhang, Yingmei ^a   Ma, Dalong ^a   Blenis, John ^b   Wang, Ying ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MOTILITY; CELLULAR TRANSFORMATION; DOWN-REGULATION; E-CADHERINS; EPITHELIAL SHEETS; ERK ACTIVATION; HEPATOCELLULAR CARCINOMA CELL; HEPATOCYTE GROWTH FACTOR; HEPATOCYTES; HEPG2 CELLS; LARGE PARTS; MALIGNANT TUMORS; MORPHOLOGICAL CHANGES; OVER-EXPRESSION; PHENOTYPIC CHANGES; SIGNAL-REGULATED KINASE; SMALL MOLECULE INHIBITOR; SOLID TUMORS; TUMOR CELL MIGRATION; TUMOR CELLS; TUMOR SUPPRESSORS; TURNING POINTS;

CELL DEATH; MORPHOLOGY; PEPTIDES;

TUMORS;

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CHEMOKINE; CHEMOKINE LIKE FACTOR LIKE MARVEL TRANSMEMBRANE DOMAIN CONTAINING 8 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; SCATTER FACTOR RECEPTOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UVOMORULIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INVASION; CELL MIGRATION; CELL MOTILITY; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENE SILENCING; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL;

CELL MOVEMENT; CELL SHAPE; CHEMOKINES; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HEP G2 CELLS; HEPATOCYTE GROWTH FACTOR; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; PROTO-ONCOGENE PROTEINS C-MET; PROTO-ONCOGENE PROTEINS P21(RAS); RNA INTERFERENCE;

EID: 84859516999     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.258236     Document Type: Article

References (45)

1. Pramanik, R., Qi, X., Borowicz, S., Choubey, D., Schultz, R. M., Han, J., and Chen, G. (2003) p38 isoforms have opposite effects on AP-1-dependent transcription through regulation of c-Jun. The determinant roles of the isoforms in the p38 MAPK signal specificity. J. Biol. Chem. 278, 4831-4839 (Pubitemid 36800988)
2. Thiery, J. P., Acloque, H., Huang, R. Y., and Nieto, M. A. (2009) Epithelialmesenchymal transitions in development and disease. Cell 139, 871-890
3. Thiery, J. P., and Sleeman, J. P. (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7, 131-142 (Pubitemid 43278296)
4. Wang, S. P., Wang, W. L., Chang, Y. L., Wu, C. T., Chao, Y. C., Kao, S. H., Yuan, A., Lin, C. W., Yang, S. C., Chan, W. K., Li, K. C., Hong, T. M., and Yang, P. C. (2009) p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat. Cell Biol. 11, 694-704
5. Polyak, K., and Weinberg, R. A. (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9, 265-273
6. Roux, P. P., and Blenis, J. (2004) ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev. 68, 320-344 (Pubitemid 38756868)
7. Anjum, R., and Blenis, J. (2008) The RSK family of kinases: emerging roles in cellular signaling. Nat. Rev. Mol. Cell Biol. 9, 747-758
8. Mendoza, M. C., Er, E. E., Zhang, W., Ballif, B. A., Elliott, H. L., Danuser, G., and Blenis, J. (2011) ERK-MAPK drives lamellipodial protrusion by activating the WAVE2 regulatory complex. Mol. Cell 41, 661-671
9. Yoshida, T., Hisamoto, T., Akiba, J., Koga, H., Nakamura, K., Tokunaga, Y., Hanada, S., Kumemura, H., Maeyama, M., Harada, M., Ogata, H., Yano, H., Kojiro, M., Ueno, T., Yoshimura, A., and Sata, M. (2006) Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene 25, 6056-6066 (Pubitemid 44562404)
10. Hwang, Y. H., Choi, J. Y., Kim, S., Chung, E. S., Kim, T., Koh, S. S., Lee, B., Bae, S. H., Kim, J., and Park, Y. M. (2004) Overexpression of c-raf-1 protooncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol. Res. 29, 113-121 (Pubitemid 38667508)
11. Hoshino, R., Chatani, Y., Yamori, T., Tsuruo, T., Oka, H., Yoshida, O., Shimada, Y., Ari-i, S., Wada, H., Fujimoto, J., and Kohno, M. (1999) Constitutive activation of the 41/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18, 813-822 (Pubitemid 29080340)
12. Schmitz, K. J., Wohlschlaeger, J., Lang, H., Sotiropoulos, G. C., Malago, M., Steveling, K., Reis, H., Cicinnati, V. R., Schmid, K. W., and Baba, H. A. (2008) Activation of the ERK and AKT signaling pathway predicts poor prognosis in hepatocellular carcinoma, and ERK activation in cancer tissue is associated with hepatitis C virus infection. J. Hepatol. 48, 83-90 (Pubitemid 350191996)
13. Thiery, J. P. (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol. 15, 740-746
14. McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W., Chang, F., Lehmann, B., Terrian, D. M., Milella, M., Tafuri, A., Stivala, F., Libra, M., Basecke, J., Evangelisti, C., Martelli, A. M., and Franklin, R. A. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation, and drug resistance. Biochim. Biophys. Acta 1773, 1263-1284 (Pubitemid 47125967)
15. Janda, E., Lehmann, K., Killisch, I., Jechlinger, M., Herzig, M., Downward, J., Beug, H., and Grünert, S. (2002) Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J. Cell Biol. 156, 299-313 (Pubitemid 34839911)
16. Shin, S., Dimitri, C. A., Yoon, S. O., Dowdle, W., and Blenis, J. (2010) ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol. Cell 38, 114-127
17. Murphy, L. O., MacKeigan, J. P., and Blenis, J. (2004) A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration. Mol. Cell. Biol. 24, 144-153 (Pubitemid 38010042)
18. Murphy, L. O., Smith, S., Chen, R. H., Fingar, D. C., and Blenis, J. (2002) Molecular interpretation of ERK signal duration by immediate early gene products. Nat. Cell Biol. 4, 556-564
19. Dimitri, C. A., Dowdle, W., MacKeigan, J. P., Blenis, J., and Murphy, L. O. (2005) Spatially separate docking sites on ERK2 regulate distinct signaling events in vivo. Curr. Biol. 15, 1319-1324 (Pubitemid 41026600)
20. Zarnegar, R., Muga, S., Enghild, J., and Michalopoulos, G. (1989) NH2- terminal amino acid sequence of rabbit hepatopoietin A, a heparin-binding polypeptide growth factor for hepatocytes. Biochem. Biophys. Res. Commun. 163, 1370-1376 (Pubitemid 19244740)
21. Yeh, J. J., Routh, E. D., Rubinas, T., Peacock, J., Martin, T. D., Shen, X. J., Sandler, R. S., Kim, H. J., Keku, T. O., and Der, C. J. (2009) KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol. Cancer Ther. 8, 834-843
22. Schlessinger, J. (2000) New roles for Src kinases in control of cell survival and angiogenesis. Cell 100, 293-296
23. Ponzetto, C., Bardelli, A., Zhen, Z., Maina, F., dalla Zonca, P., Giordano, S., Graziani, A., Panayotou, G., and Comoglio, P. M. (1994)Amultifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77, 261-271 (Pubitemid 24138623)
24. Tsukada, Y., Miyazawa, K., and Kitamura, N. (2001) High intensity ERK signal mediates hepatocyte growth factor-induced proliferation inhibition of the human hepatocellular carcinoma cell line HepG2. J. Biol. Chem. 276, 40968-40976
25. Kondo, A., Hirayama, N., Sugito, Y., Shono, M., Tanaka, T., and Kitamura, N. (2008) Coupling of Grb2 to Gab1 mediates hepatocyte growth factorinduced high intensity ERK signal required for inhibition of HepG2 hepatoma cell proliferation. J. Biol. Chem. 283, 1428-1436
26. Togawa, A., Sfakianos, J., Ishibe, S., Suzuki, S., Fujigaki, Y., Kitagawa, M., Mellman, I., and Cantley, L. G. (2010) Hepatocyte growth factor-stimulated cell scattering requires ERK and Cdc42-dependent tight junction disassembly. Biochem. Biophys. Res. Commun. 400, 271-277
27. Nagai, T., Arao, T., Furuta, K., Sakai, K., Kudo, K., Kaneda, H., Tamura, D., Aomatsu, K., Kimura, H., Fujita, Y., Matsumoto, K., Saijo, N., Kudo, M., and Nishio, K. (2011) Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol. Cancer Ther. 10, 169-177
28. Salvi, A., Arici, B., Portolani, N., Giulini, S. M., De Petro, G., and Barlati, S. (2007) In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells. Int. J. Oncol. 31, 451-460
29. Jin, C., Ding, P., Wang, Y., and Ma, D. (2005) Regulation of EGF receptor signaling by the MARVEL domain-containing protein CKLFSF8. FEBS Lett. 579, 6375-6382 (Pubitemid 41612155)
30. Li, D., Jin, C., Yin, C., Zhang, Y., Pang, B., Tian, L., Han, W., Ma, D., and Wang, Y. (2007) An alternative splice form of CMTM8 induces apoptosis. Int. J. Biochem. Cell Biol. 39, 2107-2119 (Pubitemid 47369243)
31. Jin, C., Wang, Y., Han, W., Zhang, Y., He, Q., Li, D., Yin, C., Tian, L., Liu, D., Song, Q., and Ma, D. (2007) CMTM8 induces caspase-dependent and -independent apoptosis through a mitochondria-mediated pathway. J. Cell. Physiol. 211, 112-120 (Pubitemid 46363900)
32. Debnath, J., Mills, K. R., Collins, N. L., Reginato, M. J., Muthuswamy, S. K., and Brugge, J. S. (2002) The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 111, 29-40
33. Li, N., Hill, K. S., and Elferink, L. A. (2008) Analysis of receptor tyrosine kinase internalization using flow cytometry. Methods Mol. Biol. 457, 305-317
34. Schmalhofer, O., Brabletz, S., and Brabletz, T. (2009) E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 28, 151-166
35. Lahsnig, C., Mikula, M., Petz, M., Zulehner, G., Schneller, D., van Zijl, F., Huber, H., Csiszar, A., Beug, H., and Mikulits, W. (2009) ILEI requires oncogenic Ras for the epithelial-to-mesenchymal transition of hepatocytes and liver carcinoma progression. Oncogene 28, 638-650
36. Vincan, E., and Barker, N. (2008) The upstream components of the Wnt signaling pathway in the dynamicEMTandMETassociated with colorectal cancer progression. Clin. Exp. Metastasis 25, 657-663
37. Kalluri, R., and Weinberg, R. A. (2009) The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420-1428
38. Kaposi-Novak, P., Lee, J. S., Gòmez-Quiroz, L., Coulouarn, C., Factor, V. M., and Thorgeirsson, S. S. (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Invest. 116, 1582-1595
39. Ueki, T., Fujimoto, J., Suzuki, T., Yamamoto, H., and Okamoto, E. (1997) Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology 25, 862-866 (Pubitemid 27157127)
40. Whittaker, S., Marais, R., and Zhu, A. X. (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29, 4989-5005
41. Trusolino, L., Bertotti, A., and Comoglio, P. M. (2010) MET signaling: principles and functions in development, organ regeneration, and cancer. Nat. Rev. Mol. Cell Biol. 11, 834-848
42. Lee, S. A., Ladu, S., Evert, M., Dombrowski, F., De Murtas, V., Chen, X., and Calvisi, D. F. (2010) Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis. Hepatology 52, 506-517
43. Tavian, D., De Petro, G., Benetti, A., Portolani, N., Giulini, S. M., and Barlati, S. (2000) u-PA and c-MET mRNA expression is coordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int. J. Cancer 87, 644-649 (Pubitemid 30620405)
44. Sattler, M., and Salgia, R. (2007) c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr. Oncol. Rep. 9, 102-108 (Pubitemid 46332381)
45. Sattler, M., and Salgia, R. (2009) The MET axis as a therapeutic target. Update Cancer Ther. 3, 109-118